Studies in patients with renal cell carcinoma have shown that mutations in TSC1/2 and mTOR are associated with rapalog resistance, although these mutations are not present in most patients, supporting the potential of targeting Ephexin1 in overcoming resistance68. The gene discussed is MTOR; the disease is hereditary clear cell renal cell carcinoma.